$OPCH
Option Care Health, Inc.

2023 Q2 Form 10-Q Financial Statement

#000101473923000019 Filed on May 04, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $1.069B $1.016B $915.8M
YoY Change 9.0% 10.93% 20.62%
Cost Of Revenue $818.2M $786.8M $714.8M
YoY Change 7.11% 10.07% 20.39%
Gross Profit $250.8M $229.0M $200.9M
YoY Change 15.64% 13.97% 21.43%
Gross Profit Margin 23.46% 22.54% 21.94%
Selling, General & Admin $153.6M $147.9M $134.0M
YoY Change 8.31% 10.37% 11.6%
% of Gross Profit 61.22% 64.57% 66.67%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $15.58M $14.51M $14.72M
YoY Change -2.87% -1.41% -9.9%
% of Gross Profit 6.21% 6.34% 7.33%
Operating Expenses $168.5M $162.4M $148.7M
YoY Change 6.74% 9.21% 9.03%
Operating Profit $82.37M $66.63M $52.25M
YoY Change 39.43% 27.52% 79.57%
Interest Expense -$11.80M $13.83M $12.25M
YoY Change -192.43% 12.97% -37.14%
% of Operating Profit -14.32% 20.76% 23.44%
Other Income/Expense, Net $84.94M $1.000K $2.000K
YoY Change 8493400.0% -50.0% -100.02%
Pretax Income $155.5M $54.23M $41.27M
YoY Change 226.43% 31.41% -2706.95%
Income Tax $41.10M $15.00M $11.00M
% Of Pretax Income 26.43% 27.66% 26.66%
Net Earnings $114.4M $39.21M $30.28M
YoY Change 237.18% 29.51% -1158.2%
Net Earnings / Revenue 10.7% 3.86% 3.31%
Basic Earnings Per Share $0.64 $0.22 $0.17
Diluted Earnings Per Share $0.63 $0.21 $0.17
COMMON SHARES
Basic Shares Outstanding 179.8M shares 182.0M shares 180.0M shares
Diluted Shares Outstanding 181.2M shares 182.7M shares 181.7M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $441.2M $297.8M $145.6M
YoY Change 116.21% 104.52% 33.09%
Cash & Equivalents $441.2M $297.8M $145.6M
Short-Term Investments
Other Short-Term Assets $97.63M $86.91M $76.64M
YoY Change 24.28% 13.39% 32.37%
Inventory $262.9M $249.6M $217.2M
Prepaid Expenses
Receivables $396.5M $395.2M $366.3M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.198B $1.030B $805.7M
YoY Change 36.61% 27.78% 21.21%
LONG-TERM ASSETS
Property, Plant & Equipment $186.6M $105.6M $109.1M
YoY Change 77.32% -3.2% -6.23%
Goodwill $1.541B $1.534B $1.479B
YoY Change 1.87% 3.72% 3.49%
Intangibles
YoY Change
Long-Term Investments $19.70M $18.30M $21.40M
YoY Change -9.22% -14.49% 17.58%
Other Assets $23.26M $35.97M $37.75M
YoY Change -41.95% -4.71% 72.58%
Total Long-Term Assets $2.123B $2.101B $2.073B
YoY Change 0.66% 1.37% 4.9%
TOTAL ASSETS
Total Short-Term Assets $1.198B $1.030B $805.7M
Total Long-Term Assets $2.123B $2.101B $2.073B
Total Assets $3.321B $3.130B $2.878B
YoY Change 11.22% 8.76% 9.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $467.7M $448.9M $356.1M
YoY Change 22.9% 26.05% 22.4%
Accrued Expenses $194.8M $163.7M $146.0M
YoY Change 15.41% 12.09% 24.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $6.000M $6.000M $6.000M
YoY Change 0.0% 0.0% -49.04%
Total Short-Term Liabilities $668.5M $618.6M $508.1M
YoY Change 20.38% 21.73% 20.94%
LONG-TERM LIABILITIES
Long-Term Debt $1.057B $1.058B $1.059B
YoY Change -0.15% -0.16% -5.5%
Other Long-Term Liabilities $84.23M $3.089M $13.45M
YoY Change 526.45% -77.02% 49.82%
Total Long-Term Liabilities $1.142B $1.162B $1.148B
YoY Change -0.35% 1.15% -4.48%
TOTAL LIABILITIES
Total Short-Term Liabilities $668.5M $618.6M $508.1M
Total Long-Term Liabilities $1.142B $1.162B $1.148B
Total Liabilities $1.846B $1.780B $1.657B
YoY Change 8.5% 7.47% 2.1%
SHAREHOLDERS EQUITY
Retained Earnings $344.0M $229.6M $70.14M
YoY Change 230.58% 227.38% -168.17%
Common Stock $1.188B $1.181B $1.143B
YoY Change 1.74% 3.29% 1.14%
Preferred Stock
YoY Change
Treasury Stock (at cost) $2.403M
YoY Change 0.0%
Treasury Stock Shares 383.7K shares
Shareholders Equity $1.475B $1.350B $1.222B
YoY Change
Total Liabilities & Shareholders Equity $3.321B $3.130B $2.878B
YoY Change 11.22% 8.76% 9.01%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income $114.4M $39.21M $30.28M
YoY Change 237.18% 29.51% -1158.2%
Depreciation, Depletion And Amortization $15.58M $14.51M $14.72M
YoY Change -2.87% -1.41% -9.9%
Cash From Operating Activities $169.5M $89.75M $32.68M
YoY Change 62.59% 174.63% 77.81%
INVESTING ACTIVITIES
Capital Expenditures $7.794M $5.760M $5.359M
YoY Change -265.97% 7.48% 71.6%
Acquisitions
YoY Change
Other Investing Activities -$12.86M
YoY Change -78.54%
Cash From Investing Activities -$20.65M -$5.760M -$5.359M
YoY Change -68.03% 7.48% 71.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -5.497M -$80.40M -$1.145M
YoY Change -129.29% 6922.01% -77.81%
NET CHANGE
Cash From Operating Activities 169.5M $89.75M $32.68M
Cash From Investing Activities -20.65M -$5.760M -$5.359M
Cash From Financing Activities -5.497M -$80.40M -$1.145M
Net Change In Cash 143.4M $3.590M $26.18M
YoY Change 145.34% -86.29% 159.26%
FREE CASH FLOW
Cash From Operating Activities $169.5M $89.75M $32.68M
Capital Expenditures $7.794M $5.760M $5.359M
Free Cash Flow $161.7M $83.99M $27.32M
YoY Change 48.43% 207.42% 79.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001014739
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-11993
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
OPTION CARE HEALTH, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
05-0489664
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3000 Lakeside Dr.
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300N,
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Bannockburn,
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
IL
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
60015
CY2023Q1 dei City Area Code
CityAreaCode
312
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
940-2443
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
OPCH
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
179764281 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
297776000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
294186000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
395209000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
377542000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
249643000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
224281000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
86908000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
98330000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
1029536000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
994339000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
105571000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
108321000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
70077000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
72424000 usd
CY2023Q1 bios Finite Lived Intangible Assets Net Excluding Customer Lists
FiniteLivedIntangibleAssetsNetExcludingCustomerLists
21677000 usd
CY2022Q4 bios Finite Lived Intangible Assets Net Excluding Customer Lists
FiniteLivedIntangibleAssetsNetExcludingCustomerLists
22371000 usd
CY2023Q1 bios Finite Lived Customer Lists Net
FiniteLivedCustomerListsNet
334001000 usd
CY2022Q4 bios Finite Lived Customer Lists Net
FiniteLivedCustomerListsNet
341744000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
1533569000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
1533424000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
35971000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
40313000 usd
CY2023Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
2100866000 usd
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
2118597000 usd
CY2023Q1 us-gaap Assets
Assets
3130402000 usd
CY2022Q4 us-gaap Assets
Assets
3112936000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
448890000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
378763000 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
48550000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
76906000 usd
CY2023Q1 bios Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
96279000 usd
CY2022Q4 bios Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
84302000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
18847000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
19380000 usd
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
6000000 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
6000000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
618566000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
565351000 usd
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1057787000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1058204000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
69961000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
71441000 usd
CY2023Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
30780000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
22154000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3089000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9683000 usd
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1161617000 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1161482000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
1780183000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1726833000 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
12500000 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
12500000 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
182615601 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
179756714 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
182341420 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
181957698 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
18000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
18000 usd
CY2023Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
2858887 shares
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
383722 shares
CY2023Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
78138000 usd
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
2403000 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1180992000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1176906000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
229631000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
190423000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
17716000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
21159000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1350219000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1386103000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3130402000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3112936000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1015848000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
915784000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
786843000 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
714848000 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
229005000 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
200936000 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
147866000 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
133969000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14514000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14722000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
162380000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
148691000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
66625000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
52245000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
13834000 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
12246000 usd
CY2023Q1 us-gaap Investment Income Net
InvestmentIncomeNet
1437000 usd
CY2022Q1 us-gaap Investment Income Net
InvestmentIncomeNet
1267000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000 usd
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-12396000 usd
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-10977000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
54229000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
41268000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15021000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10993000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
39208000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
30275000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
1152000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
3763000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-3443000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
11070000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3443000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
11070000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
35765000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
41345000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
181262000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
179961000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
182735000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
181681000 shares
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
39208000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
30275000 usd
CY2023Q1 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
15225000 usd
CY2022Q1 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
15979000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
5540000 usd
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
3884000 usd
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
8626000 usd
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
12996000 usd
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1083000 usd
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1049000 usd
CY2023Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1437000 usd
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1267000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5988000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4178000 usd
CY2023Q1 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
2500000 usd
CY2022Q1 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
0 usd
CY2023Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
198000 usd
CY2022Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
291000 usd
CY2023Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
17812000 usd
CY2022Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
28766000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
25362000 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
34089000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-9977000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6241000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
70127000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
76872000 usd
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-28356000 usd
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-41481000 usd
CY2023Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
14831000 usd
CY2022Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
13520000 usd
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
5271000 usd
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
4246000 usd
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
5313000 usd
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
10273000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
89752000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
32681000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5760000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5359000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5760000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5359000 usd
CY2023Q1 bios Proceeds From Payments For Stock Options Exercised Restricted Stock Vested And Tax Withholding
ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding
-1902000 usd
CY2022Q1 bios Proceeds From Payments For Stock Options Exercised Restricted Stock Vested And Tax Withholding
ProceedsFromPaymentsForStockOptionsExercisedRestrictedStockVestedAndTaxWithholding
355000 usd
CY2023Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
1500000 usd
CY2022Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
1500000 usd
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
75000000 usd
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
CY2023Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-2000000 usd
CY2022Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-80402000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1145000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3590000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
26177000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
294186000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119423000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
297776000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
145600000 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
11161000 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
5104000 usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
61000 usd
CY2023Q1 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
6527000 usd
CY2022Q1 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
6242000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1175886000 usd
CY2022Q1 bios Stock Issued Value Restricted Stock Stock Options Exercised And Tax Withholdings
StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings
-355000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4178000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
30275000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
11070000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1221764000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1386103000 usd
CY2023Q1 bios Stock Issued Value Restricted Stock Stock Options Exercised And Tax Withholdings
StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings
1902000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5988000 usd
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
75735000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
39208000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3443000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1350219000 usd
CY2023Q1 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
2475166 shares
CY2023Q1 bios Number Of Service Locations
NumberOfServiceLocations
95 pharmacy
CY2023Q1 bios Number Of Infusion Sites
NumberOfInfusionSites
73 suite
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
13100000 usd
CY2023Q1 us-gaap Contract With Customer Receivable After Allowance For Credit Loss
ContractWithCustomerReceivableAfterAllowanceForCreditLoss
48300000 usd
CY2022Q4 us-gaap Contract With Customer Receivable After Allowance For Credit Loss
ContractWithCustomerReceivableAfterAllowanceForCreditLoss
53400000 usd
CY2023Q1 us-gaap Equity Method Investments
EquityMethodInvestments
18300000 usd
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
19400000 usd
CY2023Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1400000 usd
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1300000 usd
CY2023Q1 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
2500000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1015848000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
915784000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11000000 usd
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.277
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.266
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.277
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.266
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
39208000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
30275000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
181262000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
179961000 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
39208000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
30275000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
181262000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
179961000 shares
CY2023Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1473000 shares
CY2022Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1720000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
182735000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
181681000 shares
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
7000000 usd
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
7300000 usd
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y4M24D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0538
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
20721000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
18973000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
16254000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
13537000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
11451000 usd
CY2023Q1 bios Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
27733000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
108669000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
19861000 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
88808000 usd
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3300000 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
233322000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
230289000 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
127751000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
121968000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
105571000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
108321000 usd
CY2023Q1 us-gaap Depreciation
Depreciation
6723000 usd
CY2022Q1 us-gaap Depreciation
Depreciation
8445000 usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
7500000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
1533424000 usd
CY2023Q1 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
145000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
1533569000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
549066000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
549066000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
193388000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
184951000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
355678000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
364115000 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8500000 usd
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1092500000 usd
CY2023Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
7982000 usd
CY2023Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
20731000 usd
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
1063787000 usd
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
6000000 usd
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1057787000 usd
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1094000000 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
8307000 usd
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
21489000 usd
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
1064204000 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
6000000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1058204000 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
4500000 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
6000000 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
6000000 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
6000000 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
6000000 usd
CY2023Q1 bios Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
1064000000 usd
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1092500000 usd
CY2023Q1 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
1063787000 usd
CY2023Q1 us-gaap Derivative Assets
DerivativeAssets
23673000 usd
CY2022Q4 us-gaap Derivative Assets
DerivativeAssets
28268000 usd
CY2023Q1 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
2475166 shares
CY2023Q1 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
30.30
CY2023Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
75000000 usd
CY2023Q1 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
175000000 usd
CY2023Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
75000000 usd
CY2023Q1 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
2475166 shares

Files In Submission

Name View Source Status
0001014739-23-000019-index-headers.html Edgar Link pending
0001014739-23-000019-index.html Edgar Link pending
0001014739-23-000019.txt Edgar Link pending
0001014739-23-000019-xbrl.zip Edgar Link pending
bios-20230331.htm Edgar Link pending
bios-20230331.xsd Edgar Link pending
bios-20230331_g1.jpg Edgar Link pending
ex104-bridgefacility364xda.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_16.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
opch-ex311x2023033110xq.htm Edgar Link pending
opch-ex312x2023033110xq.htm Edgar Link pending
opch-ex321x2023033110xq.htm Edgar Link pending
opch-ex322x2023033110xq.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
bios-20230331_cal.xml Edgar Link unprocessable
bios-20230331_def.xml Edgar Link unprocessable
bios-20230331_lab.xml Edgar Link unprocessable
bios-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bios-20230331_htm.xml Edgar Link completed
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending